Education
About Us
Working with TipRanks
Follow Us
Clinigence Holdings Inc (NUTX)
NASDAQ:NUTX
Top Page
Clinigence Holdings
(NASDAQ:NUTX)
Select Model
Select Model
Rating:65Neutral
Price Target:
$97.00
▼(-47.31% Downside)
Action:ReiteratedDate:03/07/26
The score is driven primarily by a strong financial rebound (profitability, cash flow, and improved leverage) and generally positive earnings-call guidance and capital allocation. These strengths are tempered by clearly bearish technical momentum (price well below key moving averages with negative MACD) and limited usable valuation inputs (P/E shown as 0.000 and no dividend yield).
Positive Factors
Strong cash generation & liquidity
Sustained operating cash flow (~$248M) and higher cash balances materially improve financial flexibility for capital spending, hospital openings, buybacks and debt service. Durable cash generation reduces reliance on external financing and supports multi-year growth and capital allocation plans.
Material margin expansion & cost efficiency
A ~10ppt gross margin lift and meaningful facility cost reductions reflect sustainable unit economics gains. Improved margins increase free cash flow per visit, make new hospital openings more accretive, and provide a structural buffer against reimbursement or volume pressure over the next 2–6 months.
Improved leverage and stronger equity base
Leverage normalization to ~0.76x after earlier stress materially strengthens the balance sheet, lowering default and refinancing risk. A rebuilt equity base supports continued M&A, hospital openings and authorized buybacks while giving management flexibility if operating volatility returns.
Negative Factors
IDR/arbitration timing and regulatory risk
Large CMS-driven true-up highlights structural exposure to IDR/arbitration processes and regulatory timing. Such events can recur or be amplified by legislative shifts (e.g., referenced Murphy Act risk), causing durable revenue and earnings lumpiness and complicating multi-quarter forecasting.
High accounts receivable & accrual volatility
Elevated AR and reliance on accruals tether cash conversion to dispute outcomes and evolving IDR data. This increases working capital strain and collection risk, reducing predictability of cash flow and potentially forcing near-term liquidity actions during adverse reimbursement or arbitration outcomes.
Multi-year margin and cash-flow volatility history
While recent years show recovery, historical swings in margins, cash flow and prior very high leverage reveal structural sensitivity to volume, arbitration outcomes and ramping hospitals. That uneven track record raises risk that gains may prove cyclically fragile over the medium term.
Clinigence Holdings (NUTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$645.97M
Dividend YieldN/A
Average Volume (3M)229.01K
Price to Earnings (P/E)15.6
Beta (1Y)2.39
Revenue Growth236.03%
EPS GrowthN/A
CountryUS
Employees800
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)1.69
Shares Outstanding6,968,350
10 Day Avg. Volume270,939
30 Day Avg. Volume229,014
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)3.35
Price to Sales (P/S)1.26
P/FCF Ratio4.49
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda2.57
Forecast
1Y Price Target
$225.00Price Target Upside22.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)19.78
Revenue Forecast (FY)$989.61M
Clinigence Holdings Business Overview & Revenue Model
Company DescriptionNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.
How the Company Makes MoneyClinigence Holdings generates revenue through multiple streams, primarily by offering subscription-based services for its software platforms that help healthcare providers manage patient data and improve care coordination. The company also earns revenue from consulting services that assist healthcare organizations in implementing its technologies effectively. Additionally, partnerships with healthcare institutions and payers enhance its market reach and diversify income sources. These partnerships often lead to joint initiatives that can result in shared revenue from improved patient care outcomes and operational efficiencies.
Clinigence Holdings Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive long‑term operational and financial story—very strong full‑year revenue growth (+82.4%), major margin and cash‑flow improvements, profitable and expanding IPAs, high patient satisfaction, and disciplined capital allocation. The principal negatives were a material, timing‑driven Q4 revenue/earnings hit from a CMS‑driven IDR true‑up and a large one‑time stock‑based compensation charge; these items created quarter volatility but appear to be nonrecurring or better understood by management. Given the substantial year‑over‑year improvements in revenue, adjusted EBITDA, cash flow and margins that outweigh the one‑time/quarterly headwinds and controllable operational initiatives underway, the overall sentiment is positive.Q4-2025 Updates
Positive Updates
Record Full-Year Revenue Growth
Total revenue of $875.3M for FY2025, up 82.4% from $479.9M in FY2024, driven by hospital division expansion and stronger collections.
Significant Adjusted EBITDA and Profit Improvement
Adjusted EBITDA increased to $259.6M in 2025 (up 152.6% from $102.8M in 2024). Operating income rose to $275.6M (vs. $130.7M prior year) and net income attributable to Nutex was $70.8M (increase of $18.7M, ~36% YoY).
Very Strong Cash Generation and Liquidity
Net cash provided by operating activities was $248.1M for the 12 months ended 12/31/2025 (up $225.0M vs $23.2M prior year). Cash on hand grew to $185.6M as of 12/31/2025, up 356.6% from $40.6M a year earlier.
Volume Growth and High Patient Satisfaction
Total hospital visits increased to 188,279 in 2025, up 11.8% from 168,388 in 2024. Mature facilities grew 1.3% for the year. The company received >8,700 patient reviews averaging a 4.8/5 rating, indicating strong patient experience.
Margin and Cost Efficiency Gains
Gross profit improved to $444.3M (50.8% of revenue) vs $196.3M (40.9%) in 2024. Facility-level operating costs declined to 49.2% of revenue from 59.1% (nearly a 10 percentage-point improvement). Excluding arbitration expenses, operational costs were 33.4% of revenue in 2025 vs 47.1% in 2024.
Strategic Growth Initiatives and Capital Deployment
Opened 3 new hospitals (Sherman, TX; St. Louis, MO; Amble, TX) in 2025/early 2026, expanded profitable IPAs (~40,000 members) and launched a $25M share repurchase program (completed) with an additional $25M authorized, reflecting disciplined capital allocation.
Negative Updates
Material Q4 Revenue Decline Due to One-Time Arbitration True-Up
Fourth quarter 2025 revenue fell to $151.7M, a 41.1% decline vs Q4 2024, primarily driven by a one-time $55M cumulative true-up related to 18,950 arbitration/IDR claims deemed ineligible (periods July 2024–Dec 2025). Management estimates Q4 adjusted revenue excluding the true-up would be ~$206.7M.
Quarterly Profitability Hit in Q4
Q4 2025 adjusted EBITDA dropped to $16.6M from $86.7M in Q4 2024 (down ~$70.1M, ~80.8% decline). Q4 operating income and net income also declined materially (operating income down $83.4M; net income attributable down $49.6M vs prior-year quarter).
Large One-Time Stock-Based Compensation Charge
Total stock-based compensation expense of $117.0M in 2025 (vs $16.6M in 2024), an increase of ~$100.4M driven by earn-out shares for under-construction/ramping hospitals — a significant noncash item that depresses GAAP earnings for 2025.
IDR/Ineligibility Backlog and Regulatory Timing Risk
CMS-directed backlog resolution produced a large, timing-driven ineligible-claim true-up (18,950 charts). While Nutex reports an ~8% ineligibility rate (better than a ~19% national average), the IDR process caused revenue timing volatility and carries ongoing regulatory uncertainty (including potential legislative changes such as the Murphy Act).
Higher Accounts Receivable and Accrual Volatility
Accounts receivable rose to $319.4M at year-end 2025 from $232.4M at 12/31/2024. Management highlights that accrual-based revenue recognition and evolving IDR data create quarter-to-quarter lumpiness and potential for future true-ups.
Modest Mature-Facility Growth and Q4 Softness
Mature hospitals posted only 1.3% growth for the full year and slightly decreased visits (-0.3%) in Q4 2025, indicating that some established locations remain challenged to drive stronger organic growth.
Company Guidance
Management's forward guidance emphasized disciplined, profitable growth with four capital priorities — share repurchases (completed $25M program and authorized an additional $25M), growth at existing hospitals (ER/inpatient volume and revenue‑per‑patient initiatives), IPA/Population Health expansion (40,000 members today; launching IPAs in Dallas and San Antonio in 2026) and a capital‑efficient real‑estate play (develop/own through stabilization with potential sale‑leasebacks). They expect three hospital openings in 2026 (Jacksonville, West Little Rock, San Antonio) with ~4 more in 2027, while operating 27 hospitals across 12 states today; operational targets include enterprise tele‑hospitalist coverage in the coming year. Key metrics to monitor: cash $185.6M, net cash from operations $248.1M (12 months), total revenue $875.3M (+82% YoY), adjusted EBITDA $259.6M (+152.6% YoY), hospital visits 188,279 (+11.8% YoY), IDR submission rate ~50–60% (historically 60–70%), prevail rate >85%, collection rate >85%, arbitration cost ~26% of arbitration revenue, and an ineligible IDR rate ~8% (vs ~19% national); management characterized the Q4 ~$55M IDR true‑up as a one‑time timing issue and urged focus on full‑year results.Clinigence Holdings Financial Statement Overview
Summary
Profitability and cash generation have rebounded strongly in 2024–2025 (higher net margin and ~51% gross margin; operating/free cash flow ~ $248M). Balance-sheet leverage improved materially (debt-to-equity down to ~0.76x in 2025). Offsetting factors are the sharp revenue decline noted in the statements and multi-year volatility in margins/cash flow, which raises durability risk.Income Statement
Profitability has recovered strongly after deep losses in 2022–2023, with 2024 and 2025 returning to solid earnings (2025 net margin ~21% vs. ~11% in 2024) and healthy gross margin expansion (~51% in 2025 vs. ~41% in 2024). However, growth is volatile: revenue fell sharply in 2025 (down ~10.8% YoY) after a large step-up in 2024, and margins have swung dramatically over the last several years, reducing confidence in durability.74
Positive
Balance Sheet
Leverage has improved meaningfully as equity rebuilt: debt-to-equity declined from very elevated levels in 2023 (~4.5x) and 2024 (~2.3x) to a more manageable ~0.76x in 2025, alongside a sharp increase in equity. Returns on equity are strong in the most recent period (~43% in 2025), but the history of negative equity returns (notably 2022–2023) and prior high leverage point to balance-sheet risk if profitability weakens again.63
Positive
Cash Flow
Cash generation strengthened materially: 2025 operating cash flow (~$248M) and free cash flow (~$248M) are robust and improved versus 2024’s much lower operating cash flow, with free cash flow growth positive in both 2024 and 2025. Cash conversion is also solid recently (free cash flow roughly matching net income in 2025), though the track record is uneven—2023 free cash flow was negative, highlighting sensitivity to operating performance.78
Positive
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 875.26M | 479.95M | 247.65M | 219.29M | 331.53M |
| Gross Profit | 444.28M | 196.26M | 34.77M | 15.42M | 179.28M |
| EBITDA | 296.15M | 148.65M | -14.58M | -394.03M | 183.45M |
| Net Income | 70.79M | 52.18M | -45.79M | -424.78M | 132.59M |
Balance Sheet | |||||
| Total Assets | 918.52M | 655.32M | 398.25M | 431.75M | 394.65M |
| Cash, Cash Equivalents and Short-Term Investments | 185.57M | 43.58M | 22.00M | 34.26M | 36.12M |
| Total Debt | 351.39M | 340.30M | 275.76M | 267.20M | 178.55M |
| Total Liabilities | 495.09M | 453.43M | 319.14M | 311.42M | 203.07M |
| Stockholders Equity | 329.45M | 146.34M | 61.45M | 95.86M | 114.65M |
Cash Flow | |||||
| Free Cash Flow | 245.60M | 20.85M | -8.24M | 35.97M | 136.51M |
| Operating Cash Flow | 248.13M | 23.15M | 1.26M | 50.61M | 173.43M |
| Investing Cash Flow | -5.24M | -2.67M | -11.24M | -4.34M | -36.98M |
| Financing Cash Flow | -97.95M | 1.09M | -2.27M | -48.13M | -125.85M |
Clinigence Holdings Technical Analysis
Negative
184.11
Price Trends
130.24
Negative
135.05
Negative
120.56
Negative
Market Momentum
-9.90
Positive
36.14
Neutral
14.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Negative. The current price of 184.11 is above the 20-day moving average (MA) of 102.06, above the 50-day MA of 130.24, and above the 200-day MA of 120.56, indicating a bearish trend. The MACD of -9.90 indicates Positive momentum. The RSI at 36.14 is Neutral, neither overbought nor oversold. The STOCH value of 14.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUTX.
Clinigence Holdings Risk Analysis
Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clinigence Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $615.60M | 37.76 | 5.87% | 0.52% | 3.68% | 5.62% | |
65 Neutral | $645.97M | 15.58 | 23.80% | ― | 236.03% | ― | |
55 Neutral | $2.13B | -46.73 | -5.69% | ― | 1.92% | 59.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $157.09M | -2.20 | -47.69% | ― | -5.30% | 46.01% | |
46 Neutral | $337.15M | -0.27 | -69.22% | ― | -16.65% | -71.92% | |
46 Neutral | $89.41M | -0.94 | -30.28% | ― | 4.64% | -17.17% |
* Healthcare Sector Average
NUTX
Clinigence Holdings
92.70
37.68
68.48%
HSTM
HealthStream
20.97
-9.91
-32.10%
EVH
Evolent Health
3.02
-6.97
-69.77%
HCAT
Health Catalyst
1.22
-3.24
-72.70%
TXG
10x Genomics
16.69
5.93
55.11%
DH
Definitive Healthcare Corp
1.10
-1.57
-58.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.